Adaeze A. Emeka

Northwestern University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

William J. Catàlona

Northwestern University

Stacy Loeb

NYU Langone Health

Antonio Finelli

Princess Margaret Cancer Centre

Brian T. Helfand

NorthShore University HealthSystem

John S. Witte

Stanford University

Christopher J. Logothetis

The University of Texas MD Anderson Cancer Center

June M. Chan

University of California, San Francisco

Leonard S. Marks

University of California, Los Angeles

Eric A. Klein

Cleveland Clinic

Celestia S. Higano

University of British Columbia

Cooperative Institutions

National Hospital

161

Northwestern University

University of California, San Francisco

University of Toronto

Johns Hopkins University

Yale University

Harvard University

Cornell University

Cleveland Clinic

Princess Margaret Cancer Centre

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Warren D.W. Heston, PhD and Neil H. Bander, MD: Founding Fathers of PSMA Technology

Urology (2022)

Connie Lippowitsch Adaeze A. Emeka William J. Catàlona

10.1016/j.urology.2022.02.018

Cite

Citations (0)

The impact of obtaining explicit informed consent for medical student participation in the pelvic examination under anesthesia: A qualitative interview study

International Journal of Gynecology & Obstetrics (2025)

Hannah C. Milad Katie Watson Patrick Eucalitto Ricky Hill Alithia Zamantakis

Institutional review board

Pelvic examination

10.1002/ijgo.70000

Cite

Citations (0)

Genetic factors associated with prostate cancer conversion from active surveillance to treatment

Human Genetics and Genomics Advances (2021)

Yu Jiang Travis J. Meyers Adaeze A. Emeka Lauren Folgosa Cooley Phillip R. Cooper

Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for prostate cancer, many men on AS eventually convert to active treatment. PC is one of the most heritable cancers, and genetic factors that predispose to aggressive tumors may help distinguish men who are more likely to discontinue AS. To investigate this, we undertook a multi-institutional genome-wide association study (GWAS) of 5,222 PC patients and 1,139 other patients from replication cohorts, all of whom initially elected AS and were followed over time for the potential outcome of conversion from AS to active treatment. In the GWAS we detected 18 variants associated with conversion, 15 of which were not previously associated with PC risk. With a transcriptome-wide association study (TWAS), we found two genes associated with conversion (

10.1016/j.xhgg.2021.100070

Cite

Citations (21)

Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort

The Journal of Urology (2021)

Lauren Folgosa Cooley Adaeze A. Emeka Travis J. Meyers Phillip R. Cooper Daniel W. Lin

No AccessJournal of UrologyAdult Urology1 Nov 2021Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional CohortThis article is commented on by the following:Editorial Comment Lauren Folgosa Cooley, Adaeze A. Emeka, Travis J. Meyers, Phillip R. Cooper, Daniel W. Lin, Antonio Finelli, James A. Eastham, Christopher J. Logothetis, Leonard S. Marks, Danny Vesprini, S. Larry Goldenberg, Celestia S. Higano, Christian P. Pavlovich, June M. Chan, Todd M. Morgan, Eric A. Klein, Daniel A. Barocas, Stacy Loeb, Brian T. Helfand, Denise M. Scholtens, John S. Witte, and William J. Catalona Lauren Folgosa CooleyLauren Folgosa Cooley Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois , Adaeze A. EmekaAdaeze A. Emeka Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois , Travis J. MeyersTravis J. Meyers Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California , Phillip R. CooperPhillip R. Cooper Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois , Daniel W. LinDaniel W. Lin Fred Hutchinson Cancer Research Center, Cancer Prevention Program, Public Health Sciences, Seattle, Washington Department of Urology, University of Washington, Seattle, Washington , Antonio FinelliAntonio Finelli Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada , James A. EasthamJames A. Eastham Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York , Christopher J. LogothetisChristopher J. Logothetis Departments of Genitourinary Medical Oncology and Urology, the University of Texas M. D. Anderson Cancer Center, Houston, Texas , Leonard S. MarksLeonard S. Marks Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California , Danny VespriniDanny Vesprini Odette Cancer Centre, Sunnybrook Health and Sciences Centre, University of Toronto, Toronto, Ontario, Canada , S. Larry GoldenbergS. Larry Goldenberg Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada , Celestia S. HiganoCelestia S. Higano Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada , Christian P. PavlovichChristian P. Pavlovich The Brady Urological Institute, the Johns Hopkins University School of Medicine, Baltimore, Maryland , June M. ChanJune M. Chan Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California Department of Urology, University of California, San Francisco, San Francisco, California , Todd M. MorganTodd M. Morgan Department of Urology, University of Michigan, Ann Arbor, Michigan , Eric A. KleinEric A. Klein Glickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, Ohio , Daniel A. BarocasDaniel A. Barocas Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee , Stacy LoebStacy Loeb Departments of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs Medical Center, New York, New York , Brian T. HelfandBrian T. Helfand Division of Urology, NorthShore University Health System, Evanston, Illinois , Denise M. ScholtensDenise M. Scholtens Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois , John S. WitteJohn S. Witte Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California Department of Urology, University of California, San Francisco, San Francisco, California Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California , and William J. CatalonaWilliam J. Catalona ‡Correspondence:Northwestern University Feinberg School of Medicine, 676 N. St. Clair St., Suite 20-150, Chicago, Illinois 60611 telephone: 312-695-4471; E-mail Address: [email protected] Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois View All Author Informationhttps://doi.org/10.1097/JU.0000000000001937AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We examined the demographic and clinicopathological parameters associated with the time to convert from active surveillance to treatment among men with prostate cancer. Materials and Methods: A multi-institutional cohort of 7,279 patients managed with active surveillance had data and biospecimens collected for germline genetic analyses. Results: Of 6,775 men included in the analysis, 2,260 (33.4%) converted to treatment at a median followup of 6.7 years. Earlier conversion was associated with higher Gleason grade groups (GG2 vs GG1 adjusted hazard ratio [aHR] 1.57, 95% CI 1.36–1.82; ≥GG3 vs GG1 aHR 1.77, 95% CI 1.29–2.43), serum prostate specific antigen concentrations (aHR per 5 ng/ml increment 1.18, 95% CI 1.11–1.25), tumor stages (cT2 vs cT1 aHR 1.58, 95% CI 1.41–1.77; ≥cT3 vs cT1 aHR 4.36, 95% CI 3.19–5.96) and number of cancerous biopsy cores (3 vs 1–2 cores aHR 1.59, 95% CI 1.37–1.84; ≥4 vs 1–2 cores aHR 3.29, 95% CI 2.94–3.69), and younger age (age continuous per 5-year increase aHR 0.96, 95% CI 0.93–0.99). Patients with high-volume GG1 tumors had a shorter interval to conversion than those with low-volume GG1 tumors and behaved like the higher-risk patients. We found no significant association between the time to conversion and self-reported race or genetic ancestry. Conclusions: A shorter time to conversion from active surveillance to treatment was associated with higher-risk clinicopathological tumor features. Furthermore, patients with high-volume GG1 tumors behaved similarly to those with intermediate and high-risk tumors. An exploratory analysis of self-reported race and genetic ancestry revealed no association with the time to conversion. References 1. : Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: Risk stratification, shared decision making, and care options. J Urol 2018; 199: 683. Link, Google Scholar 2. : The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. BJU Int 2018; 121: 737. Google Scholar 3. : Reasons for discontinuing active surveillance: assessment of 21 centres in 12 countries in the Movember GAP3 consortium. Eur Urol 2019; 75: 523. Google Scholar 4. : Determining clinically based factors associated with reclassification in the pre-MRI era using a large prospective active surveillance cohort. Urology 2020; 138: 91. Google Scholar 5. : Active surveillance review: contemporary selection criteria, follow-up, compliance and outcomes. Transl Androl Urol 2018; 7: 243. Google Scholar 6. : African American race is not associated with risk of reclassification during active surveillance: results from the Canary Prostate Cancer Active Surveillance Study. J Urol 2020; 203: 727. Link, Google Scholar 7. : Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort. Eur Urol 2020; 77: 675. Google Scholar 8. : Five-year nationwide follow-up study of active surveillance for prostate cancer. Eur Urol 2015; 67: 233. Google Scholar 9. : A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur Urol 2016; 70: 954. Google Scholar 10. : Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit Tricounty area, 1973 to 1987. Urology 1995; 45: 93. Google Scholar 11. : Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin 2016; 66: 290. Google Scholar 12. : Development and validation of a clinical prognostic stage group system for nonmetastatic prostate cancer using disease-specific mortality results from the international staging collaboration for cancer of the prostate. JAMA Oncol 2020; 6: 1912. Google Scholar 13. : Comparison by race of conservative management for low-risk and intermediate-risk prostate cancers in Veterans from 2004 to 2018. JAMA Netw Open 2020; 3: e2018318. Google Scholar 14. : Association between African American race and clinical outcomes in men treated for low-risk prostate cancer with active surveillance. JAMA 2020; 324: 1747. Google Scholar 15. : Active surveillance for low-risk prostate cancer in black patients. New Engl J Med 2019; 380: 2070. Google Scholar 16. : Prostate cancer-specific mortality across Gleason scores in black vs nonblack men. JAMA 2018; 320: 2479. Google Scholar 17. : Is active surveillance a suitable option for African American men with prostate cancer? A systemic literature review. Prostate Cancer Prostatic Dis 2017; 20: 127. Google Scholar 18. : Active surveillance for black men with low-risk prostate cancer. JAMA 2020; 324: 1733. Google Scholar 19. : Association of Black race with prostate cancer–specific and other-cause mortality. JAMA Oncol 2019; 5: 975. Google Scholar 20. : Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance. J Urol 2012; 187: 1594. Link, Google Scholar 21. Uroweb: EAU Guidelines: Prostate Cancer. Available at https://uroweb.org/guideline/prostate-cancer/. Accessed September 14, 2020. Google Scholar 22. : Prostate cancer, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019; 17: 479. Google Scholar 23. : Median follow-up in clinical trials. J Clin Oncol 1991; 9: 191. Google Scholar 24. : Fast model-based estimation of ancestry in unrelated individuals. Genome Res 2009; 19: 1655. Google Scholar 25. : 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. New Engl J Med 2016; 375: 1415. Google Scholar 26. : Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol 2015; 193: 807. Link, Google Scholar 27. : National trends in active surveillance for prostate cancer: validation of Medicare claims-based algorithms. Urology 2018; 120: 96. Google Scholar 28. : Magnetic resonance imaging-guided confirmatory biopsy for initiating active surveillance of prostate cancer. JAMA Netw Open 2019; 2: e1911019. Google Scholar 29. : Prostate magnetic resonance imaging interpretation varies substantially across radiologists. Eur Urol Focus 2019; 5: 592. Google Scholar Funding/Support and Role of the Sponsor: P50CA180995 (Catalona) 08/01/15–07/31/21 NIH/NCI SPORE in Prostate Cancer PI on the SPORE grant, Center for Inherited Disease Research (CIDR) award from the NCI for patient sample genotyping (X01HG009642), Urological Research Foundation (Catalona), NorthShore University Health System, Evanston, Illinois (Helfand). Additional support was provided by award numbers R01CA158627 and R01CA195505 (Marks), P50 CA186786 (Morgan), UL1 TR000445 from NCATS/NIH for Vanderbilt REDCap (Barocas), P50 CA097186 and K05 CA175147 (Stanford), and U01 CA113913 (Sanda) from the National Institute of Health. Conflict of Interest Disclosures: Dr. Finelli—Consultant/Advisory Board (Abbvie, Astellas, Amgen, Astra Zeneca, Bayer, Janssen, Sanofi, TerSera). Dr. Fleshner—Honoraria/advisory/speaker bureau (Astellas, Janssen, Abbvie, Ferring, Sanofi, Merck); Research funding (Janssen, Astellas, Bayer); Stock (Verity Pharma). Dr. Eastham—Stock (3D biopsy). Dr. Ehdaie—Consulting (Myriad, Inc); Honorarium (Koelis webinar). Dr. Gregg—Advisory board for Genentech, not related to the manuscript. Dr. Marks—Co-founder (Avenda Health). Dr. Higano—Institutional research funding (Aptevo, Aragon, Astellas, AstraZeneca, Clovis, Dendreon, eFFECTOR Therapeutics, Emergent, Ferring, Genentech, Hoffman-Laroche, Medivation, Pfizer); Consulting, scientific advisory boards (Astellas, Bayer, Blue Earth Diagnostics, Clovis, Dendreon, Ferring, Hinova, Janssen, Merck, Orion, Pfizer, Tolmar, Carrick Therapeutics, Novartis, Genentech); Other (spouse holds stock and former officer of CTI Biopharma). Dr. Pavlovich—Clinical trial Steering Committee member and clinical trial site Principal Investigator (PI) (Dendreon); clinical trial site PI (Profound Medical, Canada); clinical trial site PI (Nanostics, Canada). Dr. Carroll—advisory board (Nutcracker Therapeutics [messenger RNA therapy], Francis Medical [tissue ablation] and Insightec [tissue ablation]), not relevant to this study. Dr. Cooperberg—reports personal fees from Astellas, Bayer, MDx Health, Myriad Genetics, Dendreon, Steba Biotech, Astra Zeneca and Abbvie, outside the submitted work. Dr. Chan—Husband is a full-time employee of GRAIL, Inc. Dr. Barocas—Advisory Boards for Progenics. Dr. Dall'Era—Clinical trial (Janssen); Grant (Tempus); Speaker (Photocure). Dr. Rais-Bahrami—Consultant (Philips/InVivo Corp, Genomic Health Inc, Bayer Healthcare, Blue Earth Diagnostics and Intuitive Surgical). Research funding support (NIH/NCI, U.S. Department of Defense, Blue Earth Diagnostics, Genomic Health Inc, and Astellas). Dr. Karnes—Institutional and personal IP-royalties (Decipher Biosciences). Dr. Cookson—Advisory Board (Astellas, Janssen, Merck, Bayer). Dr. Stratton—Advisor (Dendreon); Honoraria (Bayer). Dr. Stadler—Consultant (DSMB; Astra-Zeneca, Bayer, Eisai, Merck, Pfizer, Sotio); Consultant (Caremark/CVS, Genentech, Pfizer); Speakers Bureau (CME providers [sponsorship unknown]: Applied Clinical Education, Dava Oncology, Global Academy for Medical Education, OncLive, PeerView, Vindico); Grant/Research Support to institution (Abbvie, Astra-Zeneca, Astellas [Medivation], Bayer, Bristol-Myers-Squibb, Boehringer-Ingelheim, Calithera, Clovis, Corvus, Eisai, Exilixis, Genentech [Roche], Johnson&Johnson [Janssen], Merck, Novartis, Pfizer, Seattle Genetics, Tesaro, X4Pharmaceuticals); Miscellaneous/Editorial (Cancer [ACS], Up-To-Date). Dr. Loeb—has equity in Gilead, unrelated to the current manuscript. Dr. Helfand—Advisory board and speaker (Ambry Genetics); Researcher and speaker (Exact Sciences); Researcher, advisory board and speaker (Blue Earth Diagnostics). Dr. Taneja—Consultant (Trod Medical, Francis Medical, Insightec, Exact Imaging); scientific advisory board (GT Biopharma); scientific investigator (MDxHealth). Dr. Gaylis—scientific advisory board (Stratify Genomics). Dr. Cooley, Dr. Emeka, Dr. Meyers, Dr. Helenowski, Ms. Lancki, Mr. Cooper, Dr. Xu, Dr. Lin, Dr. Stanford, Dr. Newcomb, Dr. Logothetis, Dr. Vesprini, Dr. Klotz, Dr. Loblaw, Dr. Goldenberg, Dr. Carter, Dr. Mamawala, Ms. Cowan, Dr. Morgan, Mr. Siddiqui, Dr. Klein, Dr. Dallmer, Dr. Kundu, Dr. Roobol, Dr. Venderbos, Dr. Sanda, Dr. Arnold, Dr. Patil, Dr. Evans, Prof. Costello, Dr. Chow, Dr. Corcoran, Dr. Gordetsky, Dr. Scherr, Mr. Flynn, Dr. Koch, Dr. Nelson, Dr. Bianco, Ms. Lopez, Dr. Amling, Dr. Scholtens, Dr. Witte, Dr. Catalona declare no conflicts of interest to disclose. Author Contributions: Study concept and design: Cooley, Emeka, Catalona, Lancki, Helfand, Meyers, Witte, Scholtens; Acquisition of data: Emeka, Cooper, Lancki, Catalona, Scholtens, Helfand, Lin, Stanford, Newcomb, Colb, Finelli, Komisarenko, Eastham, Ehdaie, Benfante, Logothetis, Gregg, Perez, Garza, Marks, Barsa, Vesprini, Mamedov, Goldenberg, Higano, Arvoska, Wu, Pavlovich, Mamawala, Carroll, Chan, Morgan, Siddiqui, Martin, Klein, Gotwald, Barocas, Dallmer, Steele, Kundu, Stockdale, Roobol, Venderbos, Sanda, Patil, Evans, Dall'Era, Vij, Costello, Chow, Rais-Bahrami, Phares, Scherr, Flynn, Karnes, Koch, Dhondt, Nelson, McBride, Cookson, Stratton, Farriester, Hemken, Stadler, Banionyte, Bianco Jr., Lopez, Loeb, Byrne, Amling, Boileau, Gaylis, Kundu; Analysis and interpretation of data: Cooley, Emeka, Meyers, Jiang, Lancki, Catalona, Helfand, Witte, Scholtens; Drafting of the manuscript: Cooley, Emeka, Catalona, Helfand, Meyers, Jiang, Witte, Scholtens; Critical revision of the manuscript for important intellectual content: Cooley, Emeka, Helfand, Catalona, Meyers, Jiang, Witte, Scholtens, Cooper, Lin, Stanford, Finelli, Eastham, Ehdaie, Logothetis, Gregg, Marks, Vesprini, Loblaw, Klotz, Kundu, Goldenberg, Higano, Pavlovich, Caroll, Cooperberg, Chan, Morgan, Klein, Barocas, Roobol, Sanda, Evans, Dall'Era, Costello, Chow, Rais-Bahrami, Scherr, Karnes, Koch, Nelson, Cookson, Stratton, Stadler, Bianco Jr., Loeb, Amling, Cooperberg, Gaylis; Final approval of the version to be published: Cooley, Emeka, Helfand, Catalona, Meyers, Jiang, Witte, Scholtens, Cooper, Lin, Stanford, Finelli, Eastham, Ehdaie, Logothetis, Gregg, Marks, Vesprini, Loblaw, Klotz, Kundu, Goldenberg, Higano, Pavlovich, Caroll, Cooperberg, Chan, Morgan, Klein, Barocas, Roobol, Sanda, Evans, Dall'Era, Costello, Chow, Rais-Bahrami, Scherr, Karnes, Koch, Nelson, Cookson, Stratton, Stadler, Bianco Jr., Loeb, Amling, Cooperberg, Gaylis; Author accountability: Cooley, Emeka, Helfand, Catalona, Meyers, Jiang, Witte, Scholtens, Cooper, Lin, Stanford, Finelli, Eastham, Ehdaie, Logothetis, Gregg, Marks, Vesprini, Loblaw, Klotz, Kundu, Goldenberg, Higano, Pavlovich, Caroll, Cooperberg, Chan, Morgan, Klein, Barocas, Roobol, Sanda, Evans, Dall'Era, Costello, Chow, Rais-Bahrami, Scherr, Karnes, Koch, Nelson, Cookson, Stratton, Stadler, Bianco Jr., Loeb, Amling, Cooperberg, Gaylis take responsibility for the integrity of the data and the accuracy of the data analysis; Statistical analysis: Meyers, Lancki, Jiang, Witte, Xu, Scholtens; Acquisition of funding: Catalona, Witte, Helfand. Contributor Names: Laurence H. Klotz1; H. Ballentine Carter2; Peter R. Carroll3; Neil E. Fleshner4; Monique J. Roobol5; Martin G. Sanda6; Christopher P. Evans7; Marc A. Dall'Era7; Janet L. Stanford8,9; Lisa F. Newcomb10,11; R. Jeffrey Karnes14; Franklin D. Gaylis15; Shilajit D. Kundu16; Michael Koch17; Joel B. Nelson18; Michael S. Cookson19; Douglas S. Scherr20; Fernando J. Bianco, Jr.21; Christopher L. Amling22; Anthony J. Costello23; Ken Chow23; Samir S. Taneja13; Niall M. Corcoran23; Matthew R. Cooperberg3,24; Justin R. Gregg25; Andrew Loblaw1; Walter M. Stadler26; Behfar Ehdaie27; Yu Jiang28; Kelly L. Stratton19; Soroush Rais-Bahrami29; Jeremiah R. Dallmer30,31; Jennifer B. Gordetsky30,32; Jeri Kim33; Jianfeng Xu34; Thomas Flynn20; Merdie Delfin35; Mufaddal Mamawala2; Isabel H. Lopez21; Janet E. Cowan36; Lionne D.F. Venderbos5; Rebecca Arnold6; Dattatraya Patil6; Javed Siddiqui37; Irene Helenowski38; Nicola Lancki38; Suzanne Kolb8,9; Maria Komisarenko4; Nicole Benfante27; Cherie A. Perez25; Sergio Garz25; Danielle Barsa35; Alexandre Mamedov1; Jacqueline Petkewicz34; Nicholas Kirwen34; Olga Arsovska12; Eugenia Wu12; Tricia Landis2; Rabia Martin39; Karen Brittain40; Paige Gotwald40; Pam Steele30; Jazmine Stockdale16; Anjali Vij7; Courtney Phares29; Courtney Rose Dhondt17; Dawn McBride18; Stephen Farriester19; Erin Hemken19; Tuula Pera26; Deimante Banionyte26; Nataliya Byrne13; Ann Martinez22; Luc Boileau22; the Prostate Cancer Foundation in Rotterdam, the Canary Prostate Active Surveillance Study (PASS). Contributor Affiliations: 1Odette Cancer Centre, Sunnybrook Health and Sciences Centre, University of Toronto, Toronto, Ontario, Canada; 2The Brady Urological Institute, the Johns Hopkins University School of Medicine, Baltimore, Maryland; 3Department of Urology, University of California, San Francisco, San Francisco, California; 4Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; 5Department of Urology, Erasmus University Medical Center, Rotterdam, the Netherlands; 6Department of Urology, Emory University School of Medicine, Atlanta, Georgia; 7Department of Urologic Surgery, University of California, Davis Medical Center, Sacramento, California; 8Fred Hutchinson Cancer Research Center, Cancer Epidemiology Program, Public Health Sciences, Seattle, Washington; 9Department of Epidemiology, University of Washington, School of Public Health, Seattle, Washington; 10Fred Hutchinson Cancer Research Center, Cancer Prevention Program, Public Health Sciences, Seattle, Washington; 11Department of Urology, University of Washington, Seattle, Washington; 12Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada; 13Departments of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs Medical Center, New York, New York; 14Mayo Clinic Department of Urology, Rochester, Minnesota; 15Genesis Healthcare Partners, Department of Urology, University of California, San Diego, San Diego, California; 16Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IllinoisL; 17Department of Urology, Indiana University School of Medicine, Indianapolis, IN; 18Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; 19Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; 20Department of Urology, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York; 21Urological Research Network, Miami Lakes, Florida; 22Department of Urology, Oregon Health and Science University, Portland, Oregon; 23Department of Urology, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia; 24Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California; 25Departments of Genitourinary Medical Oncology and Urology, the University of Texas MD Anderson Cancer Center, Houston, Texas; 26University of Chicago Comprehensive Cancer Center, Chicago, Illinois; 27Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; 28Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California; 29Department of Urology, the University of Alabama at Birmingham, Birmingham, Alabama; 30Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee; 31Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California; 32Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee; 33Merck & Co., Inc., Kenilworth, New Jersey; 34Division of Urology, NorthShore University Health System, Evanston, Illinois; 35Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California; 36Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California; 37Department of Pathology, University of Michigan, Ann Arbor, Michigan; 38Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois; 39Department of Urology, University of Michigan, Ann Arbor, Michigan; and 40Glickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, Ohio. © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited BySmith J (2021) This Month in Adult UrologyJournal of Urology, VOL. 206, NO. 5, (1083-1084), Online publication date: 1-Nov-2021.Related articlesJournal of UrologySep 10, 2021, 12:00:00 AMEditorial Comment Volume 206Issue 5November 2021Page: 1147-1156Supplementary Materials Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.Keywordsprostatic neoplasmshuman geneticsrace factorswatchful waitingAcknowledgmentsWe wish to acknowledge Julia T. Arnold, PhD, Tamara Walton, MPA, MHA, Melissa Rotunno, PhD, Barbara Thomas, PhD, and the Center for Inherited Disease Research Staff for their invaluable assistance with this project.MetricsAuthor Information Lauren Folgosa Cooley Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois These authors contributed equally to the first authorship. More articles by this author Adaeze A. Emeka Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois These authors contributed equally to the first authorship. More articles by this author Travis J. Meyers Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California These authors contributed equally to the first authorship. More articles by this author Phillip R. Cooper Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois More articles by this author Daniel W. Lin Fred Hutchinson Cancer Research Center, Cancer Prevention Program, Public Health Sciences, Seattle, Washington Department of Urology, University of Washington, Seattle, Washington More articles by this author Antonio Finelli Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada More articles by this author James A. Eastham Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York More articles by this author Christopher J. Logothetis Departments of Genitourinary Medical Oncology and Urology, the University of Texas M. D. Anderson Cancer Center, Houston, Texas More articles by this author Leonard S. Marks Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California More articles by this author Danny Vesprini Odette Cancer Centre, Sunnybrook Health and Sciences Centre, University of Toronto, Toronto, Ontario, Canada More articles by this author S. Larry Goldenberg Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author Celestia S. Higano Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author Christian P. Pavlovich The Brady Urological Institute, the Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author June M. Chan Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California Department of Urology, University of California, San Francisco, San Francisco, California More articles by this author Todd M. Morgan Department of Urology, University of Michigan, Ann Arbor, Michigan More articles by this author Eric A. Klein Glickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, Ohio More articles by this author Daniel A. Barocas Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee More articles by this author Stacy Loeb Departments of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs Medical Center, New York, New York More articles by this author Brian T. Helfand Division of Urology, NorthShore University Health System, Evanston, Illinois These authors contributed equally to the senior authorship. More articles by this author Denise M. Scholtens Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois These authors contributed equally to the senior authorship. More articles by this author John S. Witte Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California Department of Urology, University of California, San Francisco, San Francisco, California Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California These authors contributed equally to the senior authorship. More articles by this author William J. Catalona Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois ‡Correspondence:Northwestern University Feinberg School of Medicine, 676 N. St. Clair St., Suite 20-150, Chicago, Illinois 60611 telephone: 312-695-4471; E-mail Address: [email protected] These authors contributed equally to the senior authorship. More articles by this author Expand All Funding/Support and Role of the Sponsor: P50CA180995 (Catalona) 08/01/15–07/31/21 NIH/NCI SPORE in Prostate Cancer PI on the SPORE grant, Center for Inherited Disease Research (CIDR) award from the NCI for patient sample genotyping (X01HG009642), Urological Research Foundation (Catalona), NorthShore University Health System, Evanston, Illinois (Helfand). Additional support was provided by award numbers R01CA158627 and R01CA195505 (Marks), P50 CA186786 (Morgan), UL1 TR000445 from NCATS/NIH for Vanderbilt REDCap (Barocas), P50 CA097186 and K05 CA175147 (Stanford), and U01 CA113913 (Sanda) from the National Institute of Health. Conflict of Interest Disclosures: Dr. Finelli—Consultant/Advisory Board (Abbvie, Astellas, Amgen, Astra Zeneca, Bayer, Janssen, Sanofi, TerSera). Dr. Fleshner—Honoraria/advisory/speaker bureau (Astellas, Janssen, Abbvie, Ferring, Sanofi, Merck); Research funding (Janssen, Astellas, Bayer); Stock (Verity Pharma). Dr. Eastham—Stock (3D biopsy). Dr. Ehdaie—Consulting (Myriad, Inc); Honorarium (Koelis webinar). Dr. Gregg—Advisory board for Genentech, not related to the manuscript. Dr. Marks—Co-founder (Avenda Health). Dr. Higano—Institutional research funding (Aptevo, Aragon, Astellas, AstraZeneca, Clovis, Dendreon, eFFECTOR Therapeutics, Emergent, Ferring, Genentech, Hoffman-Laroche, Medivation, Pfizer); Consulting, scientific advisory boards (Astellas, Bayer, Blue Earth Diagnostics, Clovis, Dendreon, Ferring, Hinova, Janssen, Merck, Orion, Pfizer, Tolmar, Carrick Therapeutics, Novartis, Genentech); Other (spouse holds stock and former officer of CTI Biopharma). Dr. Pavlovich—Clinical trial Steering Committee member and clinical trial site Principal Investigator (PI) (Dendreon); clinical trial site PI (Profound Medical, Canada); clinical trial site PI (Nanostics, Canada). Dr. Carroll—advisory board (Nutcracker Therapeutics [messenger RNA therapy], Francis Medical [tissue ablation] and Insightec [tissue ablation]), not relevant to this study. Dr. Cooperberg—reports personal fees from Astellas, Bayer, MDx Health, Myriad Genetics, Dendreon, Steba Biotech, Astra Zeneca and Abbvie, outside the submitted work. Dr. Chan—Husband is a full-time employee of GRAIL, Inc. Dr. Barocas—Advisory Boards for Progenics. Dr. Dall'Era—Clinical trial (Janssen); Grant (Tempus); Speaker (Photocure). Dr. Rais-Bahrami—Consultant (Philips/InVivo Corp, Genomic Health Inc, Bayer Healthcare, Blue Earth Diagnostics and Intuitive Surgical). Research funding support (NIH/NCI, U.S. Department of Defense, Blue Earth Diagnostics, Genomic Health Inc, and Astellas). Dr. Karnes—Institutional and personal IP-royalties (Decipher Biosciences). Dr. Cookson—Advisory Board (Astellas, Janssen, Merck, Bayer). Dr. Stratton—Advisor (Dendreon); Honoraria (Bayer). Dr. Stadler—Consultant (DSMB; Astra-Zeneca, Bayer, Eisai, Merck, Pfizer, Sotio); Consultant (Caremark/CVS, Genentech, Pfizer); Speakers Bureau (CME providers [sponsorship unknown]: Applied Clinical Education, Dava Oncology, Global Academy for Medical Education, OncLive, PeerView, Vindico); Grant/Research Support to institution (Abbvie, Astra-Zeneca, Astellas [Medivation], Bayer, Bristol-Myers-Squibb, Boehringer-Ingelheim, Calithera, Clovis, Corvus, Eisai, Exilixis, Genentech [Roche], Johnson&Johnson [Janssen], Merck, Novartis, Pfizer, Seattle Genetics, Tesaro, X4Pharmaceuticals); Miscellaneous/Editorial (Cancer [ACS], Up-To-Date). Dr. Loeb—has equity in Gilead, unrelated to the current manuscript. Dr. Helfand—Advisory board and speaker (Ambry Genetics); Researcher and speaker (Exact Sciences); Researcher, advisory board and speaker (Blue Earth Diagnostics). Dr. Taneja—Consultant (Trod Medical, Francis Medical, Insightec, Exact Imaging); scientific advisory board (GT Biopharma); scientific investigator (MDxHealth). Dr. Gaylis—scientific advisory board (Stratify Genomics). Dr. Cooley, Dr. Emeka, Dr. Meyers, Dr. Helenowski, Ms. Lancki, Mr. Cooper, Dr. Xu, Dr. Lin, Dr. Stanford, Dr. Newcomb, Dr. Logothetis, Dr. Vesprini, Dr. Klotz, Dr. Loblaw, Dr. Goldenberg, Dr. Carter, Dr. Mamawala, Ms. Cowan, Dr. Morgan, Mr. Siddiqui, Dr. Klein, Dr. Dallmer, Dr. Kundu, Dr. Roobol, Dr. Venderbos, Dr. Sanda, Dr. Arnold, Dr. Patil, Dr. Evans, Prof. Costello, Dr. Chow, Dr. Corcoran, Dr. Gordetsky, Dr. Scherr, Mr. Flynn, Dr. Koch, Dr. Nelson, Dr. Bianco, Ms. Lopez, Dr. Amling, Dr. Scholtens, Dr. Witte, Dr. Catalona declare no conflicts of interest to disclose. Author Contributions: Study concept and design: Cooley, Emeka, Catalona, Lancki, Helfand, Meyers, Witte, Scholtens; Acquisition of data: Emeka, Cooper, Lancki, Catalona, Scholtens, Helfand, Lin, Stanford, Newcomb, Colb, Finelli, Komisarenko, Eastham, Ehdaie, Benfante, Logothetis, Gregg, Perez, Garza, Marks, Barsa, Vesprini, Mamedov, Goldenberg, Higano, Arvoska, Wu, Pavlovich, Mamawala, Carroll, Chan, Morgan, Siddiqui, Martin, Klein, Gotwald, Barocas, Dallmer, Steele, Kundu, Stockdale, Roobol, Venderbos, Sanda, Patil, Evans, Dall'Era, Vij, Costello, Chow, Rais-Bahrami, Phares, Scherr, Flynn, Karnes, Koch, Dhondt, Nelson, McBride, Cookson, Stratton, Farriester, Hemken, Stadler, Banionyte, Bianco Jr., Lopez, Loeb, Byrne, Amling, Boileau, Gaylis, Kundu; Analysis and interpretation of data: Cooley, Emeka, Meyers, Jiang, Lancki, Catalona, Helfand, Witte, Scholtens; Drafting of the manuscript: Cooley, Emeka, Catalona, Helfand, Meyers, Jiang, Witte, Scholtens; Critical revision of the manuscript for important intellectual content: Cooley, Emeka, Helfand, Catalona, Meyers, Jiang, Witte, Scholtens, Cooper, Lin, Stanford, Finelli, Eastham, Ehdaie, Logothetis, Gregg, Marks, Vesprini, Loblaw, Klotz, Kundu, Goldenberg, Higano, Pavlovich, Caroll, Cooperberg, Chan, Morgan, Klein, Barocas, Roobol, Sanda, Evans, Dall'Era, Costello, Chow, Rais-Bahrami, Scherr, Karnes, Koch, Nelson, Cookson, Stratton, Stadler, Bianco Jr., Loeb, Amling, Cooperberg, Gaylis; Final approval of the version to be published: Cooley, Emeka, Helfand, Catalona, Meyers, Jiang, Witte, Scholtens, Cooper, Lin, Stanford, Finelli, Eastham, Ehdaie, Logothetis, Gregg, Marks, Vesprini, Loblaw, Klotz, Kundu, Goldenberg, Higano, Pavlovich, Caroll, Cooperberg, Chan, Morgan, Klein, Barocas, Roobol, Sanda, Evans, Dall'Era, Costello, Chow, Rais-Bahrami, Scherr, Karnes, Koch, Nelson, Cookson, Stratton, Stadler, Bianco Jr., Loeb, Amling, Cooperberg, Gaylis; Author accountability: Cooley, Emeka, Helfand, Catalona, Meyers, Jiang, Witte, Scholtens, Cooper, Lin, Stanford, Finelli, Eastham, Ehdaie, Logothetis, Gregg, Marks, Vesprini, Loblaw, Klotz, Kundu, Goldenberg, Higano, Pavlovich, Caroll, Cooperberg, Chan, Morgan, Klein, Barocas, Roobol, Sanda, Evans, Dall'Era, Costello, Chow, Rais-Bahrami, Scherr, Karnes, Koch, Nelson, Cookson, Stratton, Stadler, Bianco Jr., Loeb, Amling, Cooperberg, Gaylis take responsibility for the integrity of the data and the accuracy of the data analysis; Statistical analysis: Meyers, Lancki, Jiang, Witte, Xu, Scholtens; Acquisition of funding: Catalona, Witte, Helfand. Contributor Names: Laurence H. Klotz1; H. Ballentine Carter2; Peter R. Carroll3; Neil E. Fleshner4; Monique J. Roobol5; Martin G. Sanda6; Christopher P. Evans7; Marc A. Dall'Era7; Janet L. Stanford8,9; Lisa F. Newcomb10,11; R. Jeffrey Karnes14; Franklin D. Gaylis15; Shilajit D. Kundu16; Michael Koch17; Joel B. Nelson18; Michael S. Cookson19; Douglas S. Scherr20; Fernando J. Bianco, Jr.21; Christopher L. Amling22; Anthony J. Costello23; Ken Chow23; Samir S. Taneja13; Niall M. Corcoran23; Matthew R. Cooperberg3,24; Justin R. Gregg25; Andrew Loblaw1; Walter M. Stadler26; Behfar Ehdaie27; Yu Jiang28; Kelly L. Stratton19; Soroush Rais-Bahrami29; Jeremiah R. Dallmer30,31; Jennifer B. Gordetsky30,32; Jeri Kim33; Jianfeng Xu34; Thomas Flynn20; Merdie Delfin35; Mufaddal Mamawala2; Isabel H. Lopez21; Janet E. Cowan36; Lionne D.F. Venderbos5; Rebecca Arnold6; Dattatraya Patil6; Javed Siddiqui37; Irene Helenowski38; Nicola Lancki38; Suzanne Kolb8,9; Maria Komisarenko4; Nicole Benfante27; Cherie A. Perez25; Sergio Garz25; Danielle Barsa35; Alexandre Mamedov1; Jacqueline Petkewicz34; Nicholas Kirwen34; Olga Arsovska12; Eugenia Wu12; Tricia Landis2; Rabia Martin39; Karen Brittain40; Paige Gotwald40; Pam Steele30; Jazmine Stockdale16; Anjali Vij7; Courtney Phares29; Courtney Rose Dhondt17; Dawn McBride18; Stephen Farriester19; Erin Hemken19; Tuula Pera26; Deimante Banionyte26; Nataliya Byrne13; Ann Martinez22; Luc Boileau22; the Prostate Cancer Foundation in Rotterdam, the Canary Prostate Active Surveillance Study (PASS). Contributor Affiliations: 1Odette Cancer Centre, Sunnybrook Health and Sciences Centre, University of Toronto, Toronto, Ontario, Canada; 2The Brady Urological Institute, the Johns Hopkins University School of Medicine, Baltimore, Maryland; 3Department of Urology, University of California, San Francisco, San Francisco, California; 4Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; 5Department of Urology, Erasmus University Medical Center, Rotterdam, the Netherlands; 6Department of Urology, Emory University School of Medicine, Atlanta, Georgia; 7Department of Urologic Surgery, University of California, Davis Medical Center, Sacramento, California; 8Fred Hutchinson Cancer Research Center, Cancer Epidemiology Program, Public Health Sciences, Seattle, Washington; 9Department of Epidemiology, University of Washington, School of Public Health, Seattle, Washington; 10Fred Hutchinson Cancer Research Center, Cancer Prevention Program, Public Health Sciences, Seattle, Washington; 11Department of Urology, University of Washington, Seattle, Washington; 12Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada; 13Departments of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs Medical Center, New York, New York; 14Mayo Clinic Department of Urology, Rochester, Minnesota; 15Genesis Healthcare Partners, Department of Urology, University of California, San Diego, San Diego, California; 16Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IllinoisL; 17Department of Urology, Indiana University School of Medicine, Indianapolis, IN; 18Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; 19Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; 20Department of Urology, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York; 21Urological Research Network, Miami Lakes, Florida; 22Department of Urology, Oregon Health and Science University, Portland, Oregon; 23Department of Urology, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia; 24Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California; 25Departments of Genitourinary Medical Oncology and Urology, the University of Texas MD Anderson Cancer Center, Houston, Texas; 26University of Chicago Comprehensive Cancer Center, Chicago, Illinois; 27Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; 28Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California; 29Department of Urology, the University of Alabama at Birmingham, Birmingham, Alabama; 30Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee; 31Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California; 32Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee; 33Merck & Co., Inc., Kenilworth, New Jersey; 34Division of Urology, NorthShore University Health System, Evanston, Illinois; 35Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California; 36Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California; 37Department of Pathology, University of Michigan, Ann Arbor, Michigan; 38Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois; 39Department of Urology, University of Michigan, Ann Arbor, Michigan; and 40Glickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, Ohio. Advertisement PDF DownloadLoading ...

10.1097/ju.0000000000001937

Cite

Citations (17)

Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment

medRxiv (Cold Spring Harbor Laboratory) (2021)

Yu Jiang Travis J. Meyers Adaeze A. Emeka Lauren Folgosa Cooley Phillip R. Cooper

Abstract Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for prostate cancer, many men on AS eventually convert to active treatment. PC is one of the most heritable cancers, and genetic factors that predispose to aggressive tumors may help distinguish men who are more likely to discontinue AS. To investigate this, we undertook a multi-institutional genome-wide association study (GWAS) of 6,361 PC patients who initially elected AS and were followed over time for the potential outcome of conversion from AS to active treatment. In the GWAS we detected 18 single nucleotide polymorphisms (SNPs) associated with conversion, 15 of which were not previously associated with PC risk. We found two genes associated with conversion ( MAST3 , p = 6.9×10 -7 and GAB2 , p = 2.0×10 -6 ). Moreover, increasing values of a previously validated 269-SNP genetic risk score (GRS) for PC was positively associated with conversion (e.g., comparing the highest to the two middle deciles gave a hazard ratio [HR] = 1.13; 95% Confidence Interval [CI]= 0.94-1.36); whereas, decreasing values of a 36-variant GRS for prostate-specific antigen (PSA) levels were positively associated with conversion (e.g., comparing the lowest to the two middle deciles gave a HR = 1.25; 95% CI, 1.04-1.50). These results suggest that germline genetics may help inform and individualize the decision of AS—or the intensity of monitoring on AS— versus treatment for the initial management of patients with low-risk PC.

Genome-wide Association Study

SNP

Decile

10.1101/2021.08.30.21262305

Cite

Citations (7)

Energy Device Preferences Among Gynecologic Surgeons

JSLS Journal of the Society of Laparoscopic & Robotic Surgeons (2023)

Lulu Yu Adaeze A. Emeka P Urbina Linda Yang Susan C. Tsai

Multiple vessel-sealing devices are available for use during laparoscopy. The objective of this study is to determine what surgeon-level and device characteristics influence the choice of advanced energy device during gynecologic laparoscopy.This is a national cross-sectional study of gynecologic surgeons conducted via social media, utilizing an online, publicly-available, anonymous survey. Gynecologic surgeons who had completed residency training were approached for participation in the survey. Survey completion was voluntary and involved no further follow-ups. The web-based survey consisted of six questions with the option to answer three additional questions if time permitted. The institutional review board determined that this study qualified for exemption.There were 92 respondents who participated in the survey. Of these, 81 completed the survey and were included in the analysis. Female respondents were younger and more frequently reported a glove size of 6.5 or less. Surgeon-level characteristics, including gender, age, glove size, case volume, region, and practice setting, were not significantly associated with preferred energy devices. Device availability in the operating room was the only characteristic associated with preferred energy devices (P-value = .0076). Other device-level characteristics such as optimal thermal spread, reduced plume, ease of use, device reliability, and teachability had no statistically significant association with preferred energy devices.Multiple advanced energy devices are available for use during gynecologic laparoscopy. These devices have varying energy profiles, thermal spread, and device size. Despite this diversity, only device availability in the operating room influenced the surgeon's preferred device selection.

Gynecologic cancer

10.4293/jsls.2023.00039

Cite

Citations (0)

AN OROGASTRIC TUBE IS NOT NECESSARY FOR LOW-RISK LAPAROSCOPY: A RANDOMIZED CONTROL TRIAL

Fertility and Sterility (2024)

Annie Gauf Kristina Karlson Adaeze A. Emeka Angela Chaudhari Susan Tsai

10.1016/j.fertnstert.2024.08.221

Cite

Citations (0)

Conservative Management of Low-Risk Prostate Cancer: A Path to Value-Based Care

Urology Practice (2022)

Franklin Gaylis Matthew R. Cooperberg Stacy Loeb Ronald C. Chen Tyler M. Seibert

No AccessUrology PracticeEditorial1 May 2022Conservative Management of Low-Risk Prostate Cancer: A Path to Value-Based Care Franklin D. Gaylis, Matthew R. Cooperberg, Stacy Loeb, Ronald C. Chen, Tyler M. Seibert, Edward Cohen, Paul Dato, Adaeze A. Emeka, Rose Prime, Sonia Romo, and William J. Catalona Franklin D. GaylisFranklin D. Gaylis *Correspondence: Genesis Healthcare Partners, 3444 Kearny Villa Rd. #300, San Diego, California 92123 telephone: 619-248-2271; email address: E-mail Address: [email protected]). Genesis Healthcare Partners, San Diego, California Department of Urology, University of California, San Francisco, California More articles by this author , Matthew R. CooperbergMatthew R. Cooperberg Department of Urology, University of California, San Francisco, San Francisco, California More articles by this author , Stacy LoebStacy Loeb Departments of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs Medical Center, New York, New York More articles by this author , Ronald C. ChenRonald C. Chen Department of Radiation Oncology, University of Kansas, Kansas City, Kansas More articles by this author , Tyler M. SeibertTyler M. Seibert Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California Department of Radiology, University of California San Diego, La Jolla, California Department of Bioengineering, University of California San Diego, La Jolla, California More articles by this author , Edward CohenEdward Cohen Genesis Healthcare Partners, San Diego, California More articles by this author , Paul DatoPaul Dato Genesis Healthcare Partners, San Diego, California More articles by this author , Adaeze A. EmekaAdaeze A. Emeka Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois More articles by this author , Rose PrimeRose Prime Genesis Healthcare Partners, San Diego, California More articles by this author , Sonia RomoSonia Romo Genesis Healthcare Partners, San Diego, California More articles by this author , and William J. CatalonaWilliam J. Catalona Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois More articles by this author View All Author Informationhttps://doi.org/10.1097/UPJ.0000000000000297AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail References 1. : What is value in health care?N Engl J Med 2010; 363: 2477. Google Scholar 2. Institute of Medicine: Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academies Press 2001. Available at https://doi.org/10.17226/10027. Google Scholar 3. 114th Congress (2015-2016): H.R.2-Medicare Access and CHIP Reauthorization Act of 2015. Available at https://www.congress.gov/bill/114th-congress/house-bill/2. Google Scholar 4. Centers for Medicare & Medicaid Services: National Health Expenditures Fact Sheet. Available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NHE-Fact-Sheet. Modified December 16, 2020. Accessed March 10, 2021. Google Scholar 5. American Urological Association: AUA Quality Registry: 2016 QCDR Measures: PQRS Measures. 2019. Available at http://www.auanet.org/Downloads/AQUA_2019%20FINAL%20QCDR%20Measures.pdf. Google Scholar 6. : Defining quality metrics for active surveillance: the Michigan Urological Surgery Improvement Collaborative experience. J Urol 2021; 207: 171. Google Scholar 7. : Variation in guideline concordant active surveillance follow-up in diverse urology practices. J Urol 2017; 197: 621. Link, Google Scholar 8. : Defining quality metrics for active surveillance: the Michigan Urological Surgery Improvement Collaborative experience. J Urol 2020; 204: 1119. Link, Google Scholar 9. : Uptake of active surveillance for very-low-risk prostate cancer in Sweden. JAMA Oncol 2017; 3: 1393. Google Scholar 10. : Elusive waste. The Fermi paradox in US health care. JAMA 2019; 322: 1458. Google Scholar 11. : Redefining Health Care: Creating Value-Based Competition on 2 Results. Boston: Harvard Business School Press 2006. Google Scholar Submitted January 6, 2022. Support: TMS: In-kind research support to Department of Radiation Oncology, University of California San Diego from GE Healthcare. Conflict of Interest: FDG: Labcorp, Urology Partners of America, Janssen Pharmaceuticals (past), Bayer Pharmaceuticals, Stratify Genomics, Specialty Networks; RCC: Astellas, Myovant (past), Accuray (past), Janssen; TMS: Varian Medical Systems, CorTechs Labs, WebMD (past); PD: Bayer (speaker bureau, consultancy), Pfizer (speaker bureau), Myovant (speaker bureau), Dendreon (speaker bureau), Janssen (speaker bureau, current), Astellas (speaker bureau, current). The authors are collaborating with UnitedHealthcare to develop an alternative Pay-for-Performance payment model to optimize quality improvement for Conservative Management of low-risk Prostate Cancer. The payment incentive will be paid to the urology group based on performance. No other payments have been received or expected. Ethics Statement: Data are exempt from Institutional Review Board review as all the data presented are de-identified and were acquired for quality improvement purposes retrospectively. © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 9Issue 3May 2022Page: 195-197 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Franklin D. Gaylis Genesis Healthcare Partners, San Diego, California Department of Urology, University of California, San Francisco, California *Correspondence: Genesis Healthcare Partners, 3444 Kearny Villa Rd. #300, San Diego, California 92123 telephone: 619-248-2271; email address: E-mail Address: [email protected]). More articles by this author Matthew R. Cooperberg Department of Urology, University of California, San Francisco, San Francisco, California More articles by this author Stacy Loeb Departments of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs Medical Center, New York, New York More articles by this author Ronald C. Chen Department of Radiation Oncology, University of Kansas, Kansas City, Kansas More articles by this author Tyler M. Seibert Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California Department of Radiology, University of California San Diego, La Jolla, California Department of Bioengineering, University of California San Diego, La Jolla, California More articles by this author Edward Cohen Genesis Healthcare Partners, San Diego, California More articles by this author Paul Dato Genesis Healthcare Partners, San Diego, California More articles by this author Adaeze A. Emeka Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois More articles by this author Rose Prime Genesis Healthcare Partners, San Diego, California More articles by this author Sonia Romo Genesis Healthcare Partners, San Diego, California More articles by this author William J. Catalona Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois More articles by this author Expand All Submitted January 6, 2022. Support: TMS: In-kind research support to Department of Radiation Oncology, University of California San Diego from GE Healthcare. Conflict of Interest: FDG: Labcorp, Urology Partners of America, Janssen Pharmaceuticals (past), Bayer Pharmaceuticals, Stratify Genomics, Specialty Networks; RCC: Astellas, Myovant (past), Accuray (past), Janssen; TMS: Varian Medical Systems, CorTechs Labs, WebMD (past); PD: Bayer (speaker bureau, consultancy), Pfizer (speaker bureau), Myovant (speaker bureau), Dendreon (speaker bureau), Janssen (speaker bureau, current), Astellas (speaker bureau, current). The authors are collaborating with UnitedHealthcare to develop an alternative Pay-for-Performance payment model to optimize quality improvement for Conservative Management of low-risk Prostate Cancer. The payment incentive will be paid to the urology group based on performance. No other payments have been received or expected. Ethics Statement: Data are exempt from Institutional Review Board review as all the data presented are de-identified and were acquired for quality improvement purposes retrospectively. Advertisement PDF downloadLoading ...

Conservative Management

10.1097/upj.0000000000000297

Cite

Citations (3)

Table of Contents

Urology (2022)

Warren Heston Neil H. Bander Connie Lippowitsch Adaeze A. Emeka William J. Catàlona

Table (database)

10.1016/s0090-4295(22)00420-4

Cite

Citations (0)

Reply by Authors

The Journal of Urology (2021)

Lauren Folgosa Cooley Adaeze A. Emeka Travis J. Meyers Phillip R. Cooper Daniel W. Lin

No AccessJournal of UrologyAdult Urology1 Nov 2021Reply by Authorsis a reply to letterEditorial Comment Lauren Folgosa Cooley, Adaeze A. Emeka, Travis J. Meyers, Phillip R. Cooper, Daniel W. Lin, Antonio Finelli, James A. Eastham, Christopher J. Logothetis, Leonard S. Marks, Danny Vesprini, S. Larry Goldenberg, Celestia S. Higano, Christian P. Pavlovich, June M. Chan, Todd M. Morgan, Eric A. Klein, Daniel A. Barocas, Stacy Loeb, Brian T. Helfand, Denise M. Scholtens, John S. Witte, and William J. Catalona Lauren Folgosa CooleyLauren Folgosa Cooley Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois These authors contributed equally to the first authorship. More articles by this author , Adaeze A. EmekaAdaeze A. Emeka Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois These authors contributed equally to the first authorship. More articles by this author , Travis J. MeyersTravis J. Meyers Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California These authors contributed equally to the first authorship. More articles by this author , Phillip R. CooperPhillip R. Cooper Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois More articles by this author , Daniel W. LinDaniel W. Lin Fred Hutchinson Cancer Research Center, Cancer Prevention Program, Public Health Sciences, Seattle, Washington Department of Urology, University of Washington, Seattle, Washington More articles by this author , Antonio FinelliAntonio Finelli Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada More articles by this author , James A. EasthamJames A. Eastham Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York More articles by this author , Christopher J. LogothetisChristopher J. Logothetis Departments of Genitourinary Medical Oncology and Urology, the University of Texas M. D. Anderson Cancer Center, Houston, Texas More articles by this author , Leonard S. MarksLeonard S. Marks Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California More articles by this author , Danny VespriniDanny Vesprini Odette Cancer Centre, Sunnybrook Health and Sciences Centre, University of Toronto, Toronto, Ontario, Canada More articles by this author , S. Larry GoldenbergS. Larry Goldenberg Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author , Celestia S. HiganoCelestia S. Higano Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author , Christian P. PavlovichChristian P. Pavlovich The Brady Urological Institute, the Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author , June M. ChanJune M. Chan Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California Department of Urology, University of California, San Francisco, San Francisco, California More articles by this author , Todd M. MorganTodd M. Morgan Department of Urology, University of Michigan, Ann Arbor, Michigan More articles by this author , Eric A. KleinEric A. Klein Glickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, Ohio More articles by this author , Daniel A. BarocasDaniel A. Barocas Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee More articles by this author , Stacy LoebStacy Loeb Departments of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs Medical Center, New York, New York More articles by this author , Brian T. HelfandBrian T. Helfand Division of Urology, NorthShore University Health System, Evanston, Illinois These authors contributed equally to the senior authorship. More articles by this author , Denise M. ScholtensDenise M. Scholtens Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois These authors contributed equally to the senior authorship. More articles by this author , John S. WitteJohn S. Witte Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California Department of Urology, University of California, San Francisco, San Francisco, California Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California These authors contributed equally to the senior authorship. More articles by this author , and William J. CatalonaWilliam J. Catalona ‡Correspondence:Northwestern University Feinberg School of Medicine, 676 N. St. Clair St., Suite 20-150, Chicago, Illinois 60611 telephone: 312-695-4471; E-mail Address: [email protected] Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois These authors contributed equally to the senior authorship. More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001937.02AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Reply by Authors." The Journal of Urology, 206(5), p. 1156 © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsRelated articlesJournal of UrologySep 10, 2021, 12:00:00 AMEditorial Comment Volume 206Issue 5November 2021Page: 1156-1156 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Lauren Folgosa Cooley Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois These authors contributed equally to the first authorship. More articles by this author Adaeze A. Emeka Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois These authors contributed equally to the first authorship. More articles by this author Travis J. Meyers Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California These authors contributed equally to the first authorship. More articles by this author Phillip R. Cooper Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois More articles by this author Daniel W. Lin Fred Hutchinson Cancer Research Center, Cancer Prevention Program, Public Health Sciences, Seattle, Washington Department of Urology, University of Washington, Seattle, Washington More articles by this author Antonio Finelli Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada More articles by this author James A. Eastham Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York More articles by this author Christopher J. Logothetis Departments of Genitourinary Medical Oncology and Urology, the University of Texas M. D. Anderson Cancer Center, Houston, Texas More articles by this author Leonard S. Marks Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California More articles by this author Danny Vesprini Odette Cancer Centre, Sunnybrook Health and Sciences Centre, University of Toronto, Toronto, Ontario, Canada More articles by this author S. Larry Goldenberg Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author Celestia S. Higano Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author Christian P. Pavlovich The Brady Urological Institute, the Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author June M. Chan Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California Department of Urology, University of California, San Francisco, San Francisco, California More articles by this author Todd M. Morgan Department of Urology, University of Michigan, Ann Arbor, Michigan More articles by this author Eric A. Klein Glickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, Ohio More articles by this author Daniel A. Barocas Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee More articles by this author Stacy Loeb Departments of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs Medical Center, New York, New York More articles by this author Brian T. Helfand Division of Urology, NorthShore University Health System, Evanston, Illinois These authors contributed equally to the senior authorship. More articles by this author Denise M. Scholtens Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois These authors contributed equally to the senior authorship. More articles by this author John S. Witte Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California Department of Urology, University of California, San Francisco, San Francisco, California Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California These authors contributed equally to the senior authorship. More articles by this author William J. Catalona Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois ‡Correspondence:Northwestern University Feinberg School of Medicine, 676 N. St. Clair St., Suite 20-150, Chicago, Illinois 60611 telephone: 312-695-4471; E-mail Address: [email protected] These authors contributed equally to the senior authorship. More articles by this author Expand All Advertisement PDF DownloadLoading ...

10.1097/ju.0000000000001937.02

Cite

Citations (0)